338 related articles for article (PubMed ID: 33846801)
1. GSG2 knockdown suppresses cholangiocarcinoma progression by regulating cell proliferation, apoptosis and migration.
Zhou J; Nie W; Yuan J; Zhang Z; Mi L; Wang C; Huang R
Oncol Rep; 2021 Jun; 45(6):. PubMed ID: 33846801
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of GSG2 inhibits prostate cancer progression in vitro and in vivo.
Yu F; Lin Y; Xu X; Liu W; Tang D; Zhou X; Wang G; Zheng Y; Xie A
Int J Oncol; 2020 Jul; 57(1):139-150. PubMed ID: 32319597
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of tripartite motif 59 (TRIM59) inhibits proliferation in cholangiocarcinoma via the PI3K/AKT/mTOR signalling pathway.
Shen H; Zhang J; Zhang Y; Feng Q; Wang H; Li G; Jiang W; Li X
Gene; 2019 May; 698():50-60. PubMed ID: 30822475
[TBL] [Abstract][Full Text] [Related]
4. Haspin knockdown can inhibit progression and development of pancreatic cancer in vitro and vivo.
Han X; Kuang T; Ren Y; Lu Z; Liao Q; Chen W
Exp Cell Res; 2019 Dec; 385(1):111605. PubMed ID: 31493385
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of PSMC2 contributes to suppression of cholangiocarcinoma development by regulating CDK1.
Duan X; Yang J; Jiang B; Duan W; Wei R; Zhang H; Mao X
Aging (Albany NY); 2021 Sep; 13(17):21325-21344. PubMed ID: 34499615
[TBL] [Abstract][Full Text] [Related]
6. IGFBP7 is associated to prognosis and could suppress cell survival in cholangiocarcinoma.
Yue C; Yang M; Tian Q; Mo F; Peng J; Ma Y; Huang Y; Wang D; Wang Y; Hu Z
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):817-825. PubMed ID: 29991293
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of celastrol by inhibition of proliferation, invasion, and migration in cholangiocarcinoma via PTEN/PI3K/Akt pathway.
Zhu B; Wei Y
Cancer Med; 2020 Jan; 9(2):783-796. PubMed ID: 31957323
[TBL] [Abstract][Full Text] [Related]
8. Long non-coding RNA HOTAIR promotes tumorigenesis and forecasts a poor prognosis in cholangiocarcinoma.
Qin W; Kang P; Xu Y; Leng K; Li Z; Huang L; Gao J; Cui Y; Zhong X
Sci Rep; 2018 Aug; 8(1):12176. PubMed ID: 30111807
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-494-dependent WDHDI inhibition suppresses epithelial-mesenchymal transition, tumor growth and metastasis in cholangiocarcinoma.
Liu B; Hu Y; Qin L; Peng XB; Huang YX
Dig Liver Dis; 2019 Mar; 51(3):397-411. PubMed ID: 30314946
[TBL] [Abstract][Full Text] [Related]
10. GSG2 facilitates the progression of human breast cancer through MDM2-mediated ubiquitination of E2F1.
Tang Y; Dai G; Yang Y; Liu H
J Transl Med; 2023 Aug; 21(1):523. PubMed ID: 37537694
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of long noncoding RNA H19 indicates a poor prognosis for cholangiocarcinoma and promotes cell migration and invasion by affecting epithelial-mesenchymal transition.
Xu Y; Wang Z; Jiang X; Cui Y
Biomed Pharmacother; 2017 Aug; 92():17-23. PubMed ID: 28528181
[TBL] [Abstract][Full Text] [Related]
12. A PLCB1-PI3K-AKT Signaling Axis Activates EMT to Promote Cholangiocarcinoma Progression.
Liang S; Guo H; Ma K; Li X; Wu D; Wang Y; Wang W; Zhang S; Cui Y; Liu Y; Sun L; Zhang B; Xin M; Zhang N; Zhou H; Liu Y; Wang J; Liu L
Cancer Res; 2021 Dec; 81(23):5889-5903. PubMed ID: 34580062
[TBL] [Abstract][Full Text] [Related]
13. Upregulated LASP-1 correlates with a malignant phenotype and its potential therapeutic role in human cholangiocarcinoma.
Zhang H; Li Z; Chu B; Zhang F; Zhang Y; Ke F; Chen Y; Xu Y; Liu S; Zhao S; Liang H; Weng M; Wu X; Li M; Wu W; Quan Z; Liu Y; Zhang Y; Gong W
Tumour Biol; 2016 Jun; 37(6):8305-15. PubMed ID: 26729195
[TBL] [Abstract][Full Text] [Related]
14. Up-regulated LINC00261 predicts a poor prognosis and promotes a metastasis by EMT process in cholangiocarcinoma.
Gao J; Qin W; Kang P; Xu Y; Leng K; Li Z; Huang L; Cui Y; Zhong X
Pathol Res Pract; 2020 Jan; 216(1):152733. PubMed ID: 31812439
[TBL] [Abstract][Full Text] [Related]
15. Long non-coding RNA MIR22HG inhibits cell proliferation and migration in cholangiocarcinoma by negatively regulating the Wnt/β-catenin signaling pathway.
Hu X; Tan Z; Yang Y; Yang P
J Gene Med; 2019 May; 21(5):e3085. PubMed ID: 30856284
[TBL] [Abstract][Full Text] [Related]
16. RPL35A promotes the progression of cholangiocarcinoma by mediating HSPA8 ubiquitination.
Zhang C; Wang Y; Wu G; Sun N; Bai H; Li X; Han S; Zhou H; Qi R; Zhang J
Biol Direct; 2024 Feb; 19(1):16. PubMed ID: 38395908
[TBL] [Abstract][Full Text] [Related]
17. Identification of chondroitin polymerizing factor (CHPF) as tumor promotor in cholangiocarcinoma through regulating cell proliferation, cell apoptosis and cell migration.
Duan X; Yang J; Jiang B; Duan W; Wei R; Zhang H; Mao X
Cell Cycle; 2021; 20(5-6):591-602. PubMed ID: 33651657
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA NNT-AS1 promotes cholangiocarcinoma cells proliferation and epithelial-to-mesenchymal transition through down-regulating miR-203.
Gu Y; Zhu Z; Pei H; Xu D; Jiang Y; Zhang L; Xiao L
Aging (Albany NY); 2020 Feb; 12(3):2333-2346. PubMed ID: 32019904
[TBL] [Abstract][Full Text] [Related]
19. LKB1 inhibits intrahepatic cholangiocarcinoma by repressing the transcriptional activity of the immune checkpoint PD-L1.
Liu Z; Li S; Zeng J; Zhou X; Li H; Liu X; Li F; Jiang B; Zhao M; Ma T
Life Sci; 2020 Sep; 257():118068. PubMed ID: 32653521
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of TTYH3 promotes epithelial-to-mesenchymal transition through Wnt/β-catenin signaling and inhibits apoptosis in cholangiocarcinoma.
Xue W; Dong B; Zhao Y; Wang Y; Yang C; Xie Y; Niu Z; Zhu C
Cell Oncol (Dordr); 2021 Dec; 44(6):1351-1361. PubMed ID: 34796468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
